Tucatinib 150mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
- Tucatinib is a selective tyrosine kinase inhibitor targeting HER2, used as part of triplet therapy after prior trastuzumab (Herceptin) and pertuzumab (Perjeta) or equivalent regimens.
- This is a hospital- or clinic-administered protocol requiring comprehensive monitoring.
- Patients must have adequate hepatic and renal function before starting.
- Tucatinib is not for use as a single agent.
Side Effects
- Diarrhea is the most frequent serious adverse effect, occurring in 82% of patients with 13% experiencing severe (Grade 3+) diarrhea.
- Severe diarrhea can cause dehydration, hypotension, acute kidney injury, and death if not managed promptly.
- Nausea and vomiting occur commonly.
- Stomatitis (mouth sores) and oral ulceration affect many patients, requiring good oral hygiene.
- Liver enzyme elevation (ALT/AST) occurs frequently and requires blood monitoring.
- Rash, joint pain, and weight loss are reported.
- Nosebleeds (epistaxis) may occur.
- Serious adverse reactions occur in 29% of patients.
- Seek immediate attention for severe diarrhea, vomiting lasting more than a few hours, or signs of dehydration.
Precautions & Warnings
- Diarrhea is a dose-limiting toxicity; patients must be counseled on management and when to seek urgent care.
- Monitor liver function tests (ALT, AST, total bilirubin) every three weeks during treatment and more frequently if abnormalities develop.
- Renal function monitoring essential; serum creatinine may increase without indicating true kidney dysfunction.
- May cause fetal harm; women of childbearing age must use effective contraception during and for one week after treatment.
- Men must also use contraception due to potential testicular toxicity.
- Strong CYP3A inhibitors require tucatinib dose reduction.
- Adequate hepatic function required for use.
- Interstitial lung disease and hepatotoxicity risk; monitor for respiratory symptoms and fatigue.
Avoid Interactions
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, protease inhibitors, clarithromycin) increase tucatinib levels and require dose reduction to 100 mg twice daily; coordinate with your doctor.
- Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) decrease tucatinib effectiveness and may require dose increase.
- Moderate CYP3A4 inhibitors and inducers also warrant monitoring and possible adjustment.
- Capecitabine and trastuzumab are required companion drugs; discontinuing either stops tucatinib benefit.
- Grapefruit and grapefruit juice must be avoided as they inhibit CYP3A4.
- Tell your healthcare provider about all medications, supplements, and herbal products before starting tucatinib therapy.
References
Frequently Asked Questions
Tucatinib (150 mg tablets) treats HER2-positive metastatic breast cancer in adults who have received at least two prior anti-HER2 treatments. It is taken with trastuzumab and capecitabine as triplet therapy. Tucatinib blocks HER2 signaling to slow cancer growth and is used only after progression on other HER2-targeted drugs.
Take Tucatinib 150 mg orally twice daily (300 mg daily total) with or without food as part of the triplet combination therapy. Dose adjustments may be necessary based on liver function or side effects. Do not stop treatment without consulting your oncologist, as all three medications are essential for efficacy.
Diarrhea is very common (82%), severe in 13%, and can cause dehydration, kidney injury, and death if untreated—manage immediately with fluids and anti-diarrheal medication. Nausea, vomiting, mouth sores, rashes, and liver enzyme elevation occur frequently. Weight loss and fatigue common. Seek urgent care for severe diarrhea or persistent vomiting.
Strong CYP3A4 inhibitors (ketoconazole, protease inhibitors) increase tucatinib levels and require dose reduction. Strong inducers (rifampin, carbamazepine) reduce effectiveness and may require dose increase. Avoid grapefruit juice. Trastuzumab and capecitabine are mandatory; do not discontinue either without medical approval.
Liver function tests (ALT, AST, bilirubin) required every three weeks; more frequent monitoring if abnormal. Blood glucose, kidney function, and heart function monitored as needed. Regular clinic visits essential for dose adjustments and toxicity management. Close follow-up critical given high diarrhea incidence and liver enzyme elevation risk.
Tucatinib may cause serious fetal harm and is not recommended in pregnancy. Women must use effective contraception during treatment and one week after. Men should also use contraception. Discuss family planning with your oncologist. Pregnancy testing may be required before starting. Do not breastfeed during Tucatinib therapy.

Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.